Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors.
暂无分享,去创建一个
K. Matthay | D. Hawkins | T. Gooley | J. Villablanca | J. Slattery | J. Sanders | K. Lindsley | J. Park | Karen L. Lindsley | T. Gooley | John T. Slattery | Douglas S. Hawkins | Jean E. Sanders | Julie R. Park
[1] M. LaQuaglia,et al. Local control with multimodality therapy for stage 4 neuroblastoma. , 2000, International journal of radiation oncology, biology, physics.
[2] M. Bernstein,et al. Topotecan in Pediatric Patients With Recurrent and Progressive Solid Tumors: A Pediatric Oncology Group Phase II Study , 1998, Journal of pediatric hematology/oncology.
[3] C. Stewart,et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] L. Grochow,et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] L. Grochow,et al. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] D. Stram,et al. Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] R. Zimmerman,et al. Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] L. Grochow,et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. , 1996, Journal of the National Cancer Institute.
[9] S. Burdach,et al. Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT Solid Tumour Registry. , 1995, Bone marrow transplantation.
[10] E. Gehan,et al. The Third Intergroup Rhabdomyosarcoma Study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] S. Baker,et al. Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Silber,et al. Surveillance scanning of children with medulloblastoma. , 1994, The New England journal of medicine.
[13] W. Furman,et al. Phase I study of topotecan for pediatric patients with malignant solid tumors. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] L. Saltz,et al. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. , 1993, Journal of the National Cancer Institute.
[15] A. Donfrancesco,et al. Localized but unresectable neuroblastoma: treatment and outcome of 145 cases. Italian Cooperative Group for Neuroblastoma. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] R. Krance,et al. High-dose chemotherapy and autologous bone marrow rescue followed by interstitial and external-beam radiotherapy in newly diagnosed pediatric malignant gliomas. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] P. Adamson,et al. The child with recurrent solid tumor. , 1991, Pediatric clinics of North America.
[18] P. Gaynon,et al. Carboplatin in childhood brain tumors: A children's cancer study group phase II trial , 1990, Cancer.
[19] F. Appelbaum,et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] K. Matthay,et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. , 1999, The New England journal of medicine.
[21] D. Zelterman,et al. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] S. Rodenhuis,et al. High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma. , 1990, Journal of pharmaceutical and biomedical analysis.